UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer

Oncology letters, 2019-03, Vol.17 (3), p.2946-2952

2019

Volltextzugriff (PDF)

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

Journal of cancer research and clinical oncology, 2020-03, Vol.146 (3), p.777-785

2020

Volltextzugriff (PDF)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

Cancer science, 2021-04, Vol.112 (4), p.1534-1544

2021

Volltextzugriff (PDF)

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Volltextzugriff (PDF)

C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Cancer discovery, 2022-11, Vol.12 (11), p.2509-2515

2022

Volltextzugriff (PDF)

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer

Clinical lung cancer, 2018-09, Vol.19 (5), p.410-417.e1

2018

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

Journal of cancer research and clinical oncology, 2020-10, Vol.146 (10), p.2659-2668

2020

Volltextzugriff (PDF)

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

BMC cancer, 2018-03, Vol.18 (1), p.302-302, Article 302

2018

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Characteristics of Japanese cypress pollen-induced allergic rhinitis by environmental challenge chamber

Allergology International, 2022-01, Vol.71 (1), p.144-146

2022

Volltextzugriff (PDF)

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.387-398

2022

Volltextzugriff (PDF)

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2078-2090

2021

Volltextzugriff (PDF)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Journal of cancer research and clinical oncology, 2021, Vol.147 (1), p.245-251

2021

Volltextzugriff (PDF)

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Clinical cancer research, 2021-05, Vol.27 (9), p.2571-2583

2021

Volltextzugriff (PDF)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.737-746

2022

Volltextzugriff (PDF)

A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study)

Japanese journal of clinical oncology, 2020-07, Vol.50 (7), p.821-825

2020

Volltextzugriff (PDF)

Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report

The Tohoku Journal of Experimental Medicine, 2019, Vol.247(4), pp.247-250

2019

Volltextzugriff (PDF)

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2022-11, Vol.173, p.35-42

2022

Volltextzugriff (PDF)

Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Allergology International, 2019-07, Vol.68 (3), p.352-362

2019

Volltextzugriff (PDF)

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Clinical lung cancer, 2022-07, Vol.23 (5), p.386-392

2022

Volltextzugriff (PDF)

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

British journal of cancer, 2021-03, Vol.124 (5), p.925-932

2021

Volltextzugriff (PDF)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis

Frontiers in oncology, 2022-01, Vol.11, p.779700-779700

2022

Volltextzugriff (PDF)

Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.362-365

2020

Volltextzugriff (PDF)

1 – 25 von 377

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(289)
Mit Volltextzugriff
(335)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(223)
Life Sciences & Biomedicine
(210)
Oncology
(154)
Humans
(125)
Male
(84)
Lung Cancer
(74)
Female
(71)
Middle Aged
(69)
Aged
(66)
Chemotherapy
(63)
Adult
(55)
Patients
(54)
Lung Neoplasms - Drug Therapy
(50)
Medicine
(48)
Non-Small Cell Lung Cancer
(47)
Respiratory System
(46)
Medicine & Public Health
(43)
Retrospective Studies
(43)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(41)
Prognosis
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Characteristics of Japanese cypress pollen-induced allergic rhinitis by environmental challenge chamber

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

A randomized phase III study comparing continuation and discontinuation of PD-1 pathway inhibitors for patients with advanced non-small-cell lung cancer (JCOG1701, SAVE study)

Development of Hepatocellular Carcinoma During Nivolumab Treatment for Recurrent Non-Small Cell Lung Cancer: A Case Report

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis

Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient

Suchergebnisse filtern